Prostatype Genomics AB AI Stock Analysis
Want to see SE:PROGEN full AI Analyst Report?
Prostatype Genomics AB (PROGEN) AI Stock Analysis
Prostatype Genomics AB
(Nasdaq OMX AB:PROGEN)
The overall score of 38 reflects a company in a highly speculative and financially distressed state. The most significant factor is the extremely weak financial performance, characterized by massive unprofitability and cash burn that threatens the company's viability. This is compounded by a bearish technical trend with the stock in a clear downtrend and a valuation that offers no support due to negative earnings and no dividend. The recent minimal revenue is the only positive signal but is far from offsetting the severe fundamental and market risks.
Prostatype Genomics AB (PROGEN) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 66.23M
- Dividend Yield
- ―
- Average Volume (3M)
- 7.65M
- Price to Earnings (P/E)
- -0.2
- Beta (1Y)
- -0.30
- Revenue Growth
- 143.94%
- EPS Growth
- 70.95%
- Country
- Sweden
- Employees
- 7
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Prostatype Genomics AB Business Overview & Revenue Model
Company Description
Prostatype Genomics AB focuses on creating, marketing, and selling sophisticated prognostic gene tests. Their primary offering, the Prostatype Test System, combines genetic expression data with key clinical measurements such as PSA levels, Gleason Sc...
Prostatype Genomics AB Financial Statement Overview
Summary
Financial performance is very weak. The company is pre-revenue with a minimal TTM revenue of 1.0M, deeply negative gross and EBIT margins, and a net loss that fully translates into significant operating cash burn of -20.9M. The balance sheet shows low debt but a rapidly shrinking equity base with a -141% return on equity, indicating the company is consuming its assets to fund losses.
Income Statement
8Very NegativeBalance Sheet
35NegativeCash Flow
15Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.01M | 594.00K | 199.00K | 1.36M | 683.00K | 10.00K |
| Gross Profit | -27.83M | -37.62M | 1.92M | 3.73M | 683.00K | 2.51M |
| EBITDA | -34.16M | -36.89M | -37.40M | -38.02M | -26.79M | -15.46M |
| Net Income | -37.90M | -44.50M | -41.05M | -41.44M | -29.09M | -15.63M |
Balance Sheet | ||||||
| Total Assets | 39.91M | 50.86M | 41.97M | 49.22M | 30.95M | 40.20M |
| Cash, Cash Equivalents and Short-Term Investments | 392.00K | 9.07M | 9.42M | 2.68M | 11.49M | 20.33M |
| Total Debt | 0 | 5.30M | 67.00K | 11.67M | 867.00K | 1.27M |
| Total Liabilities | 33.36M | 24.33M | 8.50M | 24.55M | 4.80M | 4.30M |
| Stockholders Equity | 6.55M | 26.53M | 33.47M | 24.67M | 26.15M | 35.91M |
Cash Flow | ||||||
| Free Cash Flow | -20.96M | -24.06M | -52.57M | -37.70M | -27.69M | -18.58M |
| Operating Cash Flow | -20.90M | -23.80M | -44.71M | -29.14M | -27.69M | -16.08M |
| Investing Cash Flow | -12.27M | -13.36M | -8.36M | -8.57M | 0 | -2.50M |
| Financing Cash Flow | 20.64M | 36.83M | 59.75M | 28.91M | 18.85M | 23.05M |
Prostatype Genomics AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:PROGEN, the sentiment is Negative. The current price of 0.10 is below the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.11, and below the 200-day MA of 0.23, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 40.51 is Neutral, neither overbought nor oversold. The STOCH value of 27.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:PROGEN.
Prostatype Genomics AB Peers Comparison
Overall Rating
SE:DVYSR66Neutral
SE:ACARIX45Neutral
SE:BIOVIC.B41Neutral
SE:IMMNOV39.1Underperform
SE:PROGEN38Underperform
SE:QLINEA38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 66Neutral | SEK 1.09B | 42.43 | ― | ― | 4.49% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 45Neutral | SEK 213.86M | -5.42 | -96.06% | ― | 40.61% | 32.63% | |
| 41Neutral | SEK 87.21M | -1.22 | -75.51% | ― | 56.06% | 63.95% | |
| 39Underperform | SEK 87.50M | -0.27 | -215.44% | ― | 148.66% | 66.30% | |
| 38Underperform | SEK 66.23M | -0.17 | -229.18% | ― | 143.94% | 70.95% | |
| 38Underperform | SEK 238.75M | -1.46 | -48.10% | ― | 33.26% | 90.73% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:PROGEN | Prostatype Genomics AB | 0.10 | -0.12 | -55.81% | |
| SE:IMMNOV | Immunovia AB | 0.03 | -0.15 | -82.97% | |
| SE:QLINEA | Q-linea AB | 12.60 | -13.46 | -51.65% | |
| SE:ACARIX | Acarix AB | 0.17 | -0.10 | -36.76% | |
| SE:BIOVIC.B | Biovica International AB Class B | 0.30 | -0.24 | -44.69% | |
| SE:DVYSR | Devyser Diagnostics AB | 64.50 | -44.50 | -40.83% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 30, 2026
